Literature DB >> 27330037

Long-term non-invasive ventilation in muscular dystrophy.

W Kinnear1, J Colt1,2, L Watson1,3, P Smith1,3, L Johnson1,3, S Burrows1,3, M Sovani1,3, A Khanna1,3, P Maddison2, A Wills1,2.   

Abstract

Long-term non-invasive ventilation (NIV) was introduced in the 1980s, initially mainly for patients with poliomyelitis, muscular dystrophy (MD) or scoliosis. The obesity-hypoventilation syndrome has since become the commonest reason for referral to most centres providing home-NIV. Patients with MD are numerically a much smaller part of the workload, but as their disease progresses the need for ventilatory support changes and they require regular comprehensive assessment of their condition. We have examined the trend in MD use of home-NIV in our unit over the last 25 years. The number of new referrals appears to be stabilizing at around 20-25 over a 5-year period, equivalent to approximately 0.5 per 100,000 of population per year. The mean age at commencement of home-NIV is now 37.5 years, with 5-year survival rates of 70-75%. Ten-year survival rates are just over 40%. The distance of usual place of residence from our unit is fairly stable, currently at a mean of 27 km. Excellent survival rates mean that patients with MD, while numerically small, are likely to remain an important part of the workload of centres providing home-NIV. Our data should prove useful in the planning of future services for this group of patients.

Entities:  

Keywords:  Non-invasive ventilation; muscular dystrophy; respiratory failure; respiratory muscles; ventilation

Mesh:

Year:  2016        PMID: 27330037      PMCID: PMC5720207          DOI: 10.1177/1479972316654285

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  12 in total

1.  Acute and chronic respiratory failure in patients with obesity-hypoventilation syndrome: a new challenge for noninvasive ventilation.

Authors:  Antoine Cuvelier; Jean-François Muir
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

2.  A comparison of invasive versus noninvasive full-time mechanical ventilation in Duchenne muscular dystrophy.

Authors:  P Soudon; M Steens; M Toussaint
Journal:  Chron Respir Dis       Date:  2008       Impact factor: 2.444

3.  Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia.

Authors:  S Ward; M Chatwin; S Heather; A K Simonds
Journal:  Thorax       Date:  2005-12       Impact factor: 9.139

4.  Trends in survival from muscular dystrophy in England and Wales and impact on respiratory services.

Authors:  L D Calvert; T M McKeever; W J M Kinnear; J R Britton
Journal:  Respir Med       Date:  2005-10-28       Impact factor: 3.415

5.  Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy.

Authors:  A K Simonds; F Muntoni; S Heather; S Fielding
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

6.  Respiratory failure in Pompe disease: treatment with noninvasive ventilation.

Authors:  U Mellies; F Stehling; C Dohna-Schwake; R Ragette; H Teschler; T Voit
Journal:  Neurology       Date:  2005-04-26       Impact factor: 9.910

7.  Domiciliary-assisted ventilation in patients with myotonic dystrophy.

Authors:  Anne-Marie Nugent; Ian E Smith; John M Shneerson
Journal:  Chest       Date:  2002-02       Impact factor: 9.410

8.  Nasal intermittent positive pressure ventilation. Long-term follow-up in patients with severe chronic respiratory insufficiency.

Authors:  P Leger; J M Bedicam; A Cornette; O Reybet-Degat; B Langevin; J M Polu; L Jeannin; D Robert
Journal:  Chest       Date:  1994-01       Impact factor: 9.410

9.  Efficacy of nocturnal nasal ventilation in patients with restrictive thoracic disease.

Authors:  N S Hill; S E Eveloff; C C Carlisle; S G Goff
Journal:  Am Rev Respir Dis       Date:  1992-02

10.  Outcome of domiciliary nasal intermittent positive pressure ventilation in restrictive and obstructive disorders.

Authors:  A K Simonds; M W Elliott
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.